Skip to main content
300 Collins St Melbourne hello@pivot.net
Login Signup
Home Home

Main navigation

  • About
    • Team
    • Contact
  • Research & Development
    • Innovation Engine
    • Therapeutic Focus
    • Development Strategy
    • Publications/Presentations
  • Pipeline
    • RMC-4630 (SHP2)
    • RMC-5552 (mTORC1/4EBP1)
    • SOS1
    • RAS(ON) Inhibitors
  • Investors
  • Careers

Discovery and Development of RAS(ON) Inhibitors Beyond KRAS-G12C

October 9, 2021

Steve Kelsey

 

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

 

Download presentation
Return to Media Home

Latest Publications / Presentations

RMC-9805 (RM-036), a First-in-Class, Orally-Bioavailable, Tri-Complex Covalent KRAS-G12D(ON) Inhibitor, Drives Profound Anti-Tumor Activity in KRAS-G12D Mutant Tumor Models
Direct Targeting of KRAS-G12X Mutant Cancers with RMC-6236, a First-in-Class, RAS-Selective, Orally Bioavailable, Tri-complex RAS-MULTI(ON) Inhibitor
A First-In-Class Tri-complex KRAS-G13C(ON) Inhibitor Validates Therapeutic Targeting of KRAS-G13C and Drives Tumor Regressions in Preclinical Models
RMC-6291, a Next-Generation Tri-Complex KRAS-G12C(ON) Inhibitor, Outperforms KRAS-G12C(OFF) Inhibitors in Preclinical Models of KRAS-G12C Cancers
Translating Frontier Oncology Targets to Outsmart RAS-Addicted Cancers
© Revolution Medicines, Inc.  |  700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy
Get in touch with us